AbbVie Inc.
$265.01
The Read: AbbVie's stock rallied on Q4 2025 earnings and guidance exceeding expectations, then rebounded after Q2 earnings beat but fell on guidance cuts related to the Apogee acquisition, reflecting confidence in its growth drivers versus concerns over earnings pressure.
ABBV
Hover to view data
No Data